The call, on record
HIMS bullish call
Quoted text as recorded“So, you add all of that up and you look at a company trading for three and a half time sales. I think that is an absolute steal.”@ 9:55 · open at this moment on YouTube ↗
Our interpretation
- Source published
- Jul 1, 2026
- Timeframe
- At the current valuation
- Interpreted confidence
- medium
- Specificity
- vague
Email me when HIMS calls resolve
When a tracked HIMS call is scored — hit, miss or partial — we’ll email you the result. No account needed.
Used only for these updates. Privacy
Our summary of the thesis
Strongly BullishStructured interpretation of the video, not a verbatim quotation. Check the source for conditions, emphasis and context.
The host sees Hims & Hers as a healthcare demand aggregator whose customer relationships, data and expanding specialties can reinforce one another and attract pharmaceutical supply. He regards the current sales multiple as a bargain, endorses maintaining his largest portfolio holding and sees potential for 100-fold returns if the company wins globally.
Key arguments
- Consumer choice and control of the customer interface can create platform advantages comparable to Netflix and Uber.
- Labs, AI and personalized health data can improve treatments and strengthen subscriber retention and acquisition.
- Expanding specialties create cross-selling opportunities and a subscriber-data-personalization flywheel.
- Partnerships with Novo Nordisk and access to Eli Lilly products expand supply and could support subscriber growth and revenue per subscriber.
- The host cites more than 50% of observed telehealth sales in 2025 as evidence of competitive strength.
- International acquisitions expand the addressable market and subscriber base.
- Avoiding insurance supports transparent pricing and a different incentive structure from traditional healthcare.
- The host estimates second-half revenue growth could approach 50% including Eucalyptus, making roughly 3.5 times sales attractive.
- He prioritizes platform growth over near-term profitability and sees potential for stronger monetization after achieving scale.
Counter-arguments acknowledged
- Recent growth has slowed and margins face pressure.
- GLP-1 availability changes and Novo Nordisk litigation previously disrupted the business.
- Ro's advertising campaign temporarily reduced Hims & Hers' market share.
- International expansion risks diverting management attention from the US.
- Global platform dominance remains conditional.
Hedges and caveats (from the video)
- Recent revenue growth has slowed and margins are under pressure, although the host expects these pressures to be temporary.
- Compounded GLP-1 restrictions and litigation previously created substantial headwinds.
- Ro temporarily gained market share through a major advertising campaign.
- International expansion could distract management from the US business.
- The 100-fold upside scenario depends on winning globally; it is presented as potential rather than a guaranteed outcome.
About this record
Not yet reviewed by a moderatorImported analysis · scheduled AI source. A quote, summary and outcome each need their own context. Moderator review does not certify investment performance.
- Source published
- Jul 1, 2026, 3:50 PM UTC
- First recorded by TubeRank
- Nov 1, 2026, 4:25 AM UTC
- Record last updated
- Nov 1, 2026, 4:25 AM UTC
- Moderator review recorded
- Not recorded
- Transcript provenance
- YouTube captions (manual or automatic)
- Recorded analysis processor/source label
- codex-cli-scheduled
- This can identify a workflow rather than an exact AI model version.
- Submission path version
- manual_v1
- Identifies the precomputed submission path. It does not identify an AI model version or imply human authorship.
- Outcome methodology version
- Not recorded; not audited under current rules
Recent record changes 1 shown
Nov 1, 2026, 4:25 AM UTC
source updated
- Recorded analysis processor/source label
BeforeNot recorded
Aftercodex-cli-scheduled
- Extraction or submission version
BeforeNot recorded
Aftermanual_v1
Showing up to 20 recent changes. The complete feed has 2 recorded events for this call, including its initial entry. Read the full paginated history (JSON); follow nextCursor while hasMore is true.
Stored outcome evidence
- Stored reference price
- Not recorded
- Not recorded · provider not recorded
- Target as extracted
- Not recorded
- Stated deadline as extracted
- None recorded
- Recorded outcome date
- Not recorded
- Outcome price observation
- Not recorded
- Not recorded · provider not recorded
Stored explanation
No explanation was recorded for this outcome.
Missing timestamps, providers and versions are historical gaps. Stored observations can include daily closes; they do not show every intraday touch or prove an executable trade. Read the methodology.
Why we interpreted the confidence this way
The host explicitly endorses the stock as an exceptional investment opportunity at its current valuation, but supplies no price target or return deadline.